Pascal Besman discusses lurbinectedin accelerated approval with FDA
PharmaMar to submit New Drug Application (NDA) for lurbinectedin under accelerated approval in SCLC in the USA. Pascal Besman, Pharmamar COO discusses advantages and potential limitations of the new d... Author: PharmaMar Added: 08/22/2019 (Source: Oncology Tube)
Source: Oncology Tube - August 22, 2019 Category: Cancer & Oncology Source Type: podcasts

Taofeek Owonikoko, MD Discusses lurbinectedin as a Potential Practice Changing in SCLC Treatment
Lurbinectedin, a potential practice changing drug if approved, will be the only agent available in SCLC tested with immunotherapy. PharmaMar to submit New Drug Application (NDA) for lurbinectedin unde... Author: PharmaMar Added: 08/21/2019 (Source: Oncology Tube)
Source: Oncology Tube - August 21, 2019 Category: Cancer & Oncology Source Type: podcasts

Hossein Borghaei, MD of Fox Chase Discusses new data on lurbinectedin
PharmaMar will submit New Drug Application (NDA) for lurbinectedin under accelerated approval in SCLC in the USA. Hossein Borghaei, MD of Fox Chase discusses the new data released and what advantages ... Author: PharmaMar Added: 08/21/2019 (Source: Oncology Tube)
Source: Oncology Tube - August 21, 2019 Category: Cancer & Oncology Source Type: podcasts

Hossein Borghaei, MD discusses lurbinectedin recent data and advantages and potential limitations of the new drug
PharmaMar to submit New Drug Application (NDA) for lurbinectedin under accelerated approval in SCLC in the USA. Hossein Borghaei, MD discusses the recent data released and advantages and potential lim... Author: PharmaMar Added: 08/21/2019 (Source: Oncology Tube)
Source: Oncology Tube - August 21, 2019 Category: Cancer & Oncology Source Type: podcasts